Welcome to our dedicated page for SmartKem SEC filings (Ticker: SMTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SmartKem, Inc. filings document the public-company record for an organic semiconductor technology developer with common stock listed on Nasdaq under SMTK. The filings cover material-event reports, Securities Act registration statements, notices about annual-report timing, and disclosures tied to its advanced-materials and transistor-backplane business.
Recent regulatory documents address material definitive agreements, convertible notes, preferred stock financings, warrants, private placements, resale registration matters, Nasdaq listing-compliance disclosures, officer and subsidiary governance changes, shareholder voting matters, operating and financial results, and capital-structure updates involving common stock, preferred stock, and warrant securities.
SmartKem, Inc. is registering up to 146,776,707 shares of common stock for resale by Keystone Capital Partners under a committed equity purchase agreement.
SmartKem may sell shares to Keystone over time for up to the lesser of $500 million and 19.99% of shares outstanding on March 30, 2026, subject to Nasdaq limits and a 4.99% beneficial ownership cap. Common stock outstanding was 21,202,911 shares as of April 13, 2026, and would be 167,979,618 shares if all registered shares are issued. SmartKem will receive no proceeds from Keystone’s resales, but could receive up to $500 million in gross proceeds from primary sales to Keystone, earmarked for working capital and general corporate purposes.
SmartKem, Inc. is a development-stage semiconductor materials company focused on its TRUFLEX® organic thin-film transistor platform for next‑generation displays and advanced chip packaging. It designs inks and processes in the U.K. and collaborates with partners in Taiwan and China on MicroLED backlights, AMOLED displays, biometric sensors and advanced packaging applications.
The company has generated no commercial-scale revenue and remains deeply loss‑making, with a $13.0 million comprehensive loss in 2025 and an accumulated deficit of $125.1 million. Cash and cash equivalents were $0.4 million as of December 31, 2025, which management believes is insufficient to fund operations for at least 12 months, raising substantial doubt about its ability to continue as a going concern and underscoring a need for additional capital.
During early 2026 SmartKem completed several financing transactions that included transferring its patent portfolio to a third party, while retaining process and formulation know‑how in 40 trade secrets. The company is reviewing its strategy, including display prototyping and materials formulation, and continues to build out collaborations and EDA tools to support future commercialization of its materials.
SmartKem, Inc. submitted a Form 12b-25 notifying the SEC it cannot timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company states it expects to file the Annual Report by April 15, 2025, using the 15 calendar day extension permitted by Rule 12b-25.
SmartKem, Inc. entered into a private placement of Series A Convertible Preferred Stock and warrants, expected to generate gross proceeds of $9,129,200, including the exchange of $3,750,000 of existing notes valued at $4,500,000. The deal covers 11,411.5 preferred shares with a stated value of $1,000 each, convertible into common stock at $0.5812 per share, plus warrants for 23,251,960 common shares with anti‑dilution protections and 4.99%–9.99% beneficial ownership limits.
The company also established an equity line of credit allowing sales of up to the lesser of $500,000,000 or 19.99% of outstanding common shares to a single investor at 90% of market-based pricing, subject to shareholder approval and registration. SmartKem plans to seek shareholder approval to increase authorized common shares to 5,000,000,000, authorize a reverse stock split and expand its equity plan, and to reserve 1,000,000,000 shares for the equity line. As a result of the private placement, the company believes it now meets Nasdaq’s $2.5 million stockholders’ equity requirement but is awaiting formal confirmation.
SmartKem, Inc. entered into a securities purchase agreement with institutional investors to sell 11,365,350 shares of common stock at $0.2303 per share, for gross proceeds of $2,617,440.
The shares are being issued as a takedown from an effective Form S-3 shelf registration. Closing is expected on or about March 26, 2026, subject to customary conditions. SmartKem plans to use the net proceeds for working capital and general corporate purposes.
SmartKem, Inc. is offering 11,365,350 shares of Common Stock in a registered direct offering at a purchase price of $0.2303 per share, for aggregate gross proceeds of $2,617,440, in a sale to certain institutional investors.
Net proceeds are estimated at approximately $2,457,440 to be used for working capital and general corporate purposes. Shares outstanding were 9,837,561 as of March 20, 2026, and the company estimates 21,202,911 shares outstanding after the offering. The offering is expected to settle on or about March 23, 2026.
SmartKem, Inc. entered into a new financing on March 18, 2026, agreeing to sell senior secured promissory notes with an aggregate original principal of $3,750,000 for a purchase price of $2,625,000, reflecting about a 30% original issue discount. The notes carry no interest unless there is an event of default, when they accrue at 14% annually, and they mature six months after issuance.
The notes are secured by a first-priority lien on substantially all existing and future assets of SmartKem and its subsidiaries, including certain intellectual property, with each subsidiary providing guarantees. SmartKem also entered into settlement agreements with holders of prior senior secured notes, committing to repay the outstanding principal of those notes within two business days and to make an additional aggregate cash settlement payment of $300,000, alongside assigning specified patent rights to Smartkem IP LLC and exchanging mutual releases.
SmartKem, Inc. has received a Nasdaq notice that its common stock no longer meets the exchange’s minimum bid price requirement of $1.00 per share, after trading below that level for 30 consecutive business days between January 21 and March 4, 2026. The company has 180 days, until September 1, 2026, to achieve a closing bid of at least $1.00 for 10 straight business days to regain compliance, with a possible second 180‑day period if it meets other listing standards, including $5 million in stockholders’ equity. SmartKem, which currently has less than $5 million in equity and is already before a Nasdaq Hearings Panel over a separate equity‑rule deficiency, is evaluating options such as a reverse stock split while acknowledging there is no assurance it will maintain its Nasdaq Capital Market listing.
SmartKem, Inc. reports that Nasdaq has moved to delist its common stock because the company has not met the required $2.5 million stockholders’ equity standard for continued listing on The Nasdaq Capital Market. SmartKem previously received a 180-day extension through February 11, 2026 to regain compliance but remained below the equity threshold.
On February 12, 2026, Nasdaq staff notified the company that its securities will be delisted unless SmartKem promptly requests a hearing before a Nasdaq Hearings Panel. SmartKem plans to request this hearing, which would temporarily halt suspension or delisting while the Panel reviews the case and considers any extension. The company cautions that there is no assurance the Panel will grant an extension or that SmartKem will regain compliance, and notes that a faster-than-typical hearing or decision timeline could be unfavorable for maintaining its Nasdaq listing.
SmartKem, Inc. entered into a debt conversion agreement that eliminates approximately $2,016,821 of obligations owed by its subsidiary through the issuance of equity securities. The creditor received 385,130 shares of common stock at an ascribed price of $2.75 per share and pre-funded warrants to purchase 348,260 shares at an exercise price of $0.0001 per share.
The pre-funded warrants are immediately exercisable but include a beneficial ownership cap of 4.99%, adjustable up to 9.99% with 61 days’ notice. The transaction was structured as a private, unregistered issuance under Section 4(a)(2) of the Securities Act, reducing accounts payable with no cash consideration and lowering ongoing cash requirements.